1. Scrip
  2. >>Business

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

As Drug’s 2022 Sales Exceed €5bn

 
• By Ayisha Sharma

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.  

Red kidney model on a pair of outstretched hands on pink background
Chronic Kidney Disease Affects 37 Million People In The US • Source: Shutterstock

Boehringer Ingelheim GmbH is confident it can maximize the profits of the blockbuster cardiovascular and diabetes drug Jardiance through the second half of the decade as it prepares for an important label expansion into chronic kidney disease (CKD).

Total net sales from the private firm’s human pharma business grew to €18.46bn in 2022 from €15

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.